

Treatment Refractory Ocular Symptoms in Myasthenia Gravis: Clinical and Therapeutic Profile CK Symposium

Bhavana Sharma MD, Mamatha Pasnoor MD, Mazen M Dimachkie MD, Richard J. Barohn MD, Omar
Jawdat MD, Melanie Glenn MD, Constantine Farmakidis MD, Duaa Jabari MD

February 23, 2018

Background

- ▶ Most MG patients develop ocular symptoms over the course of the disease
- ▶ Despite many therapeutic options available for management of MG, some patients remain resistant to standard therapies
- ▶ Limited literature is available regarding management of refractory ocular symptoms

Objectives:

To review clinical characteristics of patients with treatment resistant ocular symptoms in myasthenia gravis (MG)



Methods:

- ▶ Retrospective chart review after IRB approval
- ▶ Neuromuscular Research Database at KUMC
- ▶ Information on MG patients with ocular symptoms between January 2013 and December 2017 was obtained and reviewed
- ▶ Treatment resistance was defined as persistent diplopia or ptosis despite adequate trial of prednisone and at least one additional immunosuppressive agent
- ▶ Demographic, clinical, diagnostic and therapeutic information were extracted from the charts

Results: Demographics


Treatment resistant group

- ▶ Patients with treatment resistant ocular symptoms with acetylcholine receptor antibody positive MG : 5
- ▶ Gender: F:M=3:2
- ▶ Age at symptoms onset
Mean=32, Median=27

Treatment responsive group

- ▶ Patients with treatment responsive ocular symptoms: 36
- ▶ Gender: F:M=12:24
- ▶ Age at onset of symptoms:
Mean=52, Median=59

Age at onset of symptoms



Results: Symptoms

- 1) In the refractory group 3/5 patients had ocular symptoms at the onset of disease and 2 of these patients progressed to have generalized disease
- 2) In the responsive group 34/36 patients had ocular symptoms at onset of disease and 8 progressed to have generalized disease

Presence of other autoimmune diseases

Treatment refractory group:


- ▶ Two patients had positive thyroid peroxidase and thyroglobulin antibodies
- ▶ One patient was diagnosed with type 1 DM

Treatment responsive group:

- ▶ Two had psoriasis
- ▶ Two had mixed connective tissue disease
- ▶ One had Hashimoto's thyroiditis

Results: Symptoms

The median time between the onset of symptoms and development of refractory ocular symptoms was 13 years (range of 3 to 25)



Results:

Diagnostic testing

- 1) In the refractory group all patients had positive AChR Ab
- 2) In the responsive group
 - 1) 21/36 had AChR Ab positive
 - 2) 1 MUSK positive
 - 3) Rest diagnosed with RNS and SFEMG

Results:

Interval between symptom onset and starting high dose steroids

- All patients in both groups were initially managed with pyridostigmine
- Most of these patients were started on high dose steroids within 6 months of the symptom onset

	Treatment refractory group Total N: 5	Treatment responsive group Total N: 36
Soon after symptom onset	3	7
3-6 months after the onset	1	27
2-8 years after the onset	1	2

Results:

Refractory group

Other immunomodulators used in the refractory group were:

- 1) Cellcept (2 patients)
 - 2) Imuran (1 patient)
 - 3) Cyclosporine (1 patient)
 - 4) IVIG (4 patients)
 - 5) PLEX (3 patients)
 - 6) Thymectomy (1 patient)
- ▶ 3/5 patients in the refractory group required ICU admission for exacerbation

Responsive group

Patients in the treatment responsive group were treated with

- 1) Cellcept (5 patients)
 - 2) Imuran (2 patients)
 - 3) Methotrexate (2 patients)
 - 4) IVIG (3 patients)
 - 5) PLEX (3 patients)
 - 6) Thymectomy (3 patients)
- ▶ 5/36 patients in the responsive group required hospital admission for exacerbation

Discussion - Ocular Symptoms Response to Treatment

- ▶ Benatar's group showed that treatment failure for ocular MG was 17% in the prednisone group (1/6 patients)
- ▶ Kupersmith et al reported that 27% of OMG patients treated with steroids (13/48) had refractory ocular symptoms
- ▶ Our study showed that ocular symptoms were refractory in 12% of the patients (5/41), all treated with prednisone and additional immunomodulatory therapy.

Discussion - Progression to Generalized MG

- Progression to generalized MG in myasthenia patients treated with prednisone was variable in the literature.
- Mittal et al showed that 38 patients with ocular myasthenia treated with prednisone and none of them progressed to generalized MG
- Monsul et al reported that 3/27 (11%) patients with ocular MG treated with prednisone developed generalized MG
- In our study, 27% of the patients with ocular onset developed generalized MG in spite of prednisone treatment.

Conclusion

- ▶ MG patients with treatment refractory ocular symptoms were mostly younger at symptom onset
- ▶ Duration between the onset of MG to the development of refractory ocular symptoms was variable
- ▶ Starting steroid therapy early was effective in resolving the ocular symptoms in most patients but a subgroup progressed to have refractory ocular symptoms
- ▶ More patients in the refractory group generalized compared to the responsive group

Questions & Discussion

THANKS



References

- 1- Mittal MK¹, Barohn RJ, Pasnoor M, McVey A, Herbelin L, Whittaker T, Dimachkie M. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response. *J Clin Neuromuscul Dis*. 2011 Sep;13(1):46-52. doi: 10.1097/CND.0b013e31821c5634.
- 2- Smith SV¹, Lee AG². Update on Ocular Myasthenia Gravis. *Neurol Clin*. 2017 Feb;35(1):115-123. doi: 10.1016/j.ncl.2016.08.008.
- 3- Barton JJ¹, Fouladvand M. Ocular aspects of myasthenia gravis. *Semin Neurol*. 2000;20(1):7-20.
- 4- Elrod RD¹, Weinberg DA. Ocular myasthenia gravis. *Ophthalmol Clin North Am*. 2004 Sep;17(3):275-309.
- 5- Weinberg DA¹, Lesser RL, Vollmer TL. Ocular myasthenia: a protean disorder. *Surv Ophthalmol*. 1994 Nov-Dec;39(3):169-210.
- 6- Vaphiades MS¹, Bhatti MT, Lesser RL. Ocular myasthenia gravis. *Curr Opin Ophthalmol*. 2012 Nov;23(6):537-42. doi: 10.1097/ICU.0b013e328358b94a.
- 7- Michael Benatar, Henry J. Kaminski; The medical treatment of ocular myasthenia (an evidence-based review; *Neurology* Jun 2007, 68 (24) 2144-2149; DOI: 10.1212/01.wnl.0000263481.14289.90

References

- 8- Kupersmith MJ1, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. *Br J Ophthalmol*. 2005 Oct;89(10):1330-4.
- 9- Kupersmith MJ1, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. *Arch Neurol*. 2003 Feb;60(2):243-8.
- 10- Monsul NT1, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. *J Neurol Sci*. 2004 Feb 15;217(2):131-3.
- 11- Benatar M1, Kaminski HJ; Quality Standards Subcommittee of the American Academy of Neurology. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2007 Jun 12;68(24):2144-9. Epub 2007 Apr 25.
- 12- Daniel B. Drachman. Myasthenia Gravis. *N Engl J Med* 1994; 330:1797-1810 June 23, 1994 DOI: 10.1056/NEJM199406233302507.